177Lu-JH04 in Patients with FAP-Positive Tumors

NCT06636617 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Patients with Advanced Metastatic FAP-Positive Tumors

Interventions

DRUG: 3.70 GBq (100 mCi) of 177Lu-JH04
DRUG: 5.55 GBq (150 mCi) of 177Lu-JH04
DRUG: 7.40 GBq (200 mCi) of 177Lu-JH04

Sponsor

First Affiliated Hospital of Fujian Medical University